Epsilon M&A Deal Report - Instituto Estudios Celulares y Moleculares
Transaction Multiples for the Valuation of Private Companies
Atrys Health / Instituto Estudios Celulares y Moleculares
No EMAT :
103464
Announced Date :
30/09/2020
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Atrys Health
Target :
Instituto Estudios Celulares y Moleculares
Country :
Spain
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
Business Description :
Founded in 1997, Instituto de Estudios Celulares y Moleculares (ICM) is a genetic and genomic diagnosis laboratory based in Spain. > Offers its services to a significant number of laboratories in...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|
|
|
||
| Current |
|
|
Rating :
***
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 50
| Date | Acquirer | Target | Country | Multiples | See details |
| 04/11/2020 | Medica Group | Global Diagnostics (Ireland) | Ireland | ** | 103410 |
| 27/10/2020 | Repligen | ARTeSYN Biosolutions Ireland | Ireland | ** | 103381 |
Source: Epsilon Research / EMAT
